GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
作者： Sang-Uk Kang
DOI: 10.1016/J.DRUDIS.2013.09.011
关键词: Pharmacology 、 Intensive care medicine 、 Orally active 、 GPR119 、 Pharmaceutical industry 、 Clinical trial 、 Gpr119 agonist 、 Type 2 Diabetes Mellitus 、 SWOT analysis 、 Medicine
摘要: Ever since its advent as a promising therapeutic target for type 2 diabetes mellitus (T2DM), G-protein-coupled receptor 119 (GPR119) has received much interest from the pharmaceutical industry. This peaked in June 2010, when Sanofi-Aventis agreed to pay Metabolex (Cymabay Therapeutics) US$375 million MBX-2982, which was representative orally active GPR119 agonist. However, opted terminate deal May 2011 and another leading agonist, GSK1292263, had loss of efficacy during clinical trial. In this review, I discuss pros cons through strengths, weaknesses, opportunities, threats (SWOT) analysis propose development strategies eventual success agonist program.
elsevier.com
sci-hub.se 参考文章(57)
Robert M. Jones, James N. Leonard, Chapter 7 The Emergence of GPR119 Agonists as Anti-Diabetic Agents Annual Reports in Medicinal Chemistry. ,vol. 44, pp. 149- 170 ,(2009) , 10.1016/S0065-7743(09)04407-8
Daisuke Matsuda, Hiroshi Tomoda, DGAT inhibitors for obesity. Current opinion in investigational drugs. ,vol. 8, pp. 836- 841 ,(2007)
Unmesh Shah, GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders. Current Opinion in Drug Discovery & Development. ,vol. 12, pp. 519- 532 ,(2009)
H A Overton, M C T Fyfe, C Reynet, GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesity British Journal of Pharmacology. ,vol. 153, ,(2008) , 10.1038/SJ.BJP.0707529
Unmesh Shah, Timothy J. Kowalski, GPR119 Agonists for the Potential Treatment of Type 2 Diabetes and Related Metabolic Disorders Incretins and Insulin Secretion. ,vol. 84, pp. 415- 448 ,(2010) , 10.1016/B978-0-12-381517-0.00016-3
Leo Thomas, Michael Mark, Gerd Luippold, Peter Eickelmann, Combination therapy for the treatment of diabetes and related conditions ,(2009)
Unmesh G. Shah, Joel M. Harris, Craig D. Boyle, Andrew W. Stamford, Hong Liu, Santhosh Francis Neelamkavil, Jinsong Hao, Bernard R. Neustadt, Samuel Chackalamannil, Pyrimidinone derivatives and methods of use thereof ,(2008)
Jie Gao, Lei Tian, Guobin Weng, Nicholas V. Bhagroo, Robert L. Sorenson, Timothy D. O’Brien, Jian Luo, Zhiguang Guo, Stimulating beta cell replication and improving islet graft function by GPR119 agonists. Transplant International. ,vol. 24, pp. 1124- 1134 ,(2011) , 10.1111/J.1432-2277.2011.01332.X
Andrew J. Carpenter, Gregory Peckham, Jing Fang, Chemical Compounds and Uses ,(2009)
Ethan Hoffmann, Jeff Wald, Siva Lavu, John Roberts, Claire Beaumont, Jon Haddad, Peter Elliott, Christoph Westphal, Eric Jacobson, Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man British Journal of Clinical Pharmacology. ,vol. 75, pp. 186- 196 ,(2013) , 10.1111/J.1365-2125.2012.04340.X